monoclonal antibodies Articles
-
In Vivo Biotin Recombinant Antibodies
Yeast produces biotinylated recombinant antibodies in vivo. Researchers have now developed a new method to generate in vivo biotinylated recombinant antibodies secreted by yeast. In vivo biotinylation supports efficient biotinylation for accurate testing. Yeast is a single-celled fungal organism that has played an important role in the field of biogenetics in recent years. Based on the expansion ...
-
Application of Capillary Electrophoresis Technology in Biopharmaceuticals
Capillary Electrophoresis (CE) is an analytical technique used in the development and quality control of protein drugs. From medium optimization, clone screening, formulation stability research and purification process monitoring, to protein characterization, related impurity detection, protein structure identification and protein drug product quality control, CE is required in all aspects of ...
-
Immobilising of anti-HPV18 and E. coli O157:H7 antibodies on magnetic silica-coated Fe
3O4for early diagnosis of cervical cancer and diarrhoeThis paper presents the synthesis and properties of magnetic silica-coated Fe3O4 nanoparticles. Uncoated Fe3O4 nanoparticles with an average diameter of 9-16 nm and saturation magnetisation of around 66 emu/g were first prepared by co-precipitation method. After being coated by SiO2 using the sol-gel method, the diameters of the coated particles ranged from 29 nm to 230 nm and their corresponding ...
-
Cancer stem–like cells photothermolysed by gold nanorod–mediated near–infrared laser irradiation
Several studies have recently identified CD133 as a marker of cancer stem–like cells (CSCs) for various tumours. Such findings make CD133 a potential molecular target for tumour–selective therapeutic approach. In this study, fluorescence–tagged CD133 monoclonal antibody (anti–CD133) was conjugated to gold nanorods (GNRs), which are one of the anisotropic nanomaterials that can absorb ...
-
Possible treatment of human multiple myeloma found
Multiple myeloma is an essentially incurable plasma cell cancer with a very poor prognosis for patients; however, in a recent study published in Science Translational Medicine entitled "Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the protein CD98 heavy chain," scientists from Osaka University in Japan have discovered the CD98 heavy chain, a common ...
By Profacgen
-
CSX-1004: A Promising Canidate in the Fight Against the Fentanyl Crisis
The opioid crisis in the United States is a devastating public health issue, with over 70,000 overdose deaths annually, largely driven by the highly potent synthetic opioid fentanyl. The urgency to address this crisis has spurred the development of innovative therapies to prevent and reverse fentanyl overdoses. In this blog, we will explore the groundbreaking preclinical work on CSX-1004, a fully ...
-
Abzymes Research is a New Field of Enzyme Engineering
Abzyme, also known as catalytic antibody, is a type of immunoglobulin with catalytic ability, that is, an antibody with catalytic activity prepared through a series of chemical and biotechnological methods. It not only has the corresponding immune activity, but also can catalyze a certain chemical reaction like an enzyme. In 1946, Pauling used the transition state theory to clarify the essence ...
-
Biopharma PEG Supplies PEG Products For Click Chemistry Reactions
What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous ...
-
ADCs Customized Linkers
Antibody Drug Conjugates (ADCs) use targeting ability of monoclonal antibodies to deliver potent cytototoxic payloads to their intended target. The linker encompasses a conjugating functionality suitable for attachment to the antibody, a spacer unit that typically incorporates a hydrophilic element and a trigger which releases the potent cytototoxic warhead. The properties that an optimal linker ...
-
Scientists Find Smart Human Antibody Neutralizes Ebola and Its Deadly Relatives
A research team's latest study shows that two human antibodies can simultaneously target two Ebola viruses: Ebola and Sudan. These two species have caused the largest and deadliest outbreaks. The new report suggests that researchers could combine these two potent antibodies to create an effective antiviral therapy. The work is published in Cell in the paper, “Asymmetric and ...
-
Application of site-identification by ligand competitive saturation in computer-aided drug design
Abstract Site Identification by Ligand Competitive Saturation (SILCS) is a molecular simulation approach that uses diverse small solutes in aqueous solution to obtain functional group affinity patterns of a protein or other macromolecule. This involves employing a combined Grand Canonical Monte Carlo (GCMC)-molecular dynamics (MD) method to sample the full 3D space of the protein, including ...
-
Antibody Selection for ADC Drugs
Antibodies are the precise guidance components of ADCs. In theory, molecules that bring effector molecules to the surface of tumor cells can play the role of antibody guidance The choice of antibody for ADC drugs depends on the target of the disease. Targets can be divided into tumor-specific antigens (TSA) and tumor-associated antigens (TAA) according to their expression. Antigens that are only ...
By BOC Sciences
-
Revealing the Details of Changes in Spike Proteins of SARS-CoV-2 Omicron Mutant Strains
The interesting SARS-CoV-2 omicron mutant strain evades immunity mediated by antibodies from vaccination or infection with early mutants due to the accumulation of a large number of spike mutations. Recently, in a research report titled "Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement" published in Science, scientists from institutions such as the University of ...
-
Three generations of ADC: Nearly a decade of development-PI
Antibody-drug conjugate (ADC), a compound that connects a cytotoxic small-molecule drug to a monoclonal antibody via a rationally established linker, which selectively delivers an efficient cytotoxic agent into the tumor, has made significant progress in the previous decade. The first ADC drug approved by the US FDA was gemtuzumab ozogamicin (Mylotarg) in 2009. Currently, the FDA has authorized ...
-
An Introduction of Intact Mass Analysis - Protein Characterization by Mass Spectrometry
As the field of biotechnology continues its inexorable march towards unfathomable frontiers, the characterization of proteins emerges as a critical linchpin in this progressive process. In this context, intact mass analysis by mass spectrometry serves as an indispensable tool of the trade, empowering researchers to achieve a thorough understanding of these enigmatic molecules. Intact mass ...
-
Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cells
Abstract We previously generated 32 rotavirus-specific (RV-specific) recombinant monoclonal antibodies (mAbs) derived from B cells isolated from human intestinal resections. Twenty-four of these mAbs were specific for the VP8* fragment of RV VP4, and most (20 of 24) were non-neutralizing when tested in the conventional MA104 cell–based assay. We reexamined the ability of these mAbs to ...
-
Three generations of ADC: Nearly a decade of development-PII
Kadcyla and second-generation non-cleavable linkers Alternative linker design methodologies are still under development. Immunogen discovered a very powerful ADC by an accidental discovery. The lysine residue of trastuzumab is linked to DM1 via a non-cleavable linker containing N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), an ADC (T-DM1, Kadcyla) authorized by the FDA in ...
-
PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ...
-
Antibody-Drug Conjugates: New Strategies of ADC Payloads
The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal antibodies, that the era of ADC drug development truly began. Driven by increasingly mature technology, ADC drugs have gone through three iterations (Fig. 1). Although ADCs have gone through three iterations, current ...
By BOC Sciences
-
Clinical Pharmacology of Antibody-Drug Conjugates
Unlike the development of most small or large molecules, which typically measures only one part or the metabolite for pharmacokinetic analysis, multiple parts of ADCs need to be measured to characterize their PK properties. Therefore, a thorough understanding of the clinical pharmacology of ADCs is critical for selecting a safe and effective dose for patients. Biological Analysis of ADC In order ...
By BOC Sciences
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you